CAMBRIDGE, Mass.--(BUSINESS WIRE)--Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that it has been selected for addition to the NASDAQ Biotechnology Index (NBI), which will become effective prior to market open on Monday, May 24, 2010.
